Cardiology | |
---|---|
Study Name | Principal Investigator |
ARTEMIS – Effects of Ziltivekimab versus Placebo on Cardiovascular Outcomes in Patients with Acute Myocardial Infarction. Read more. |
Angel Mulkay, MD |
DAPA ACT HF-TIMI 68 – A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Trial to Evaluate the Effect of In-Hospital Initiation of Dapagliflozin on Clinical Outcomes in Patients with Heart Failure with Reduced Ejection Fraction Who Have Been Stabilized During Hospitalization for Acute Heart Failure. Read more. |
Angel Mulkay, MD |
70033093AFL3002 – A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor Xia Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation (LIBREXIA-AF). Read more. |
Angel Mulkay, MD |
TRANSFORM – A Randomized Comparison of Cleerly Coronary Artery Disease Stage-Based Care Versus Risk Factor-Based Care for Primary Prevention of Cardiovascular Events (202302CPC). Read more. |
Jaffar Raza, MD and Jeffrey Goldman, MD |